AZIMUNE randomised 40 adults with uncontrolled asthma to azithromycin 500 mg three times weekly or placebo for twelve weeks. Bronchial epithelial cells were sampled by bronchoscopy at baseline and at week twelve, then cultured and infected with rhinovirus ex vivo.
Azithromycin increased rhinovirus-induced interferon-beta (p=0.047) and interferon-lambda (p=0.013) compared with baseline, with no change in the placebo group, and reduced IL-33 (p=0.001). Thymic stromal lymphopoietin was unaffected. Clinical outcomes improved numerically but not significantly against placebo.
This is a mechanistic study and should be read as one. Forty patients, sixteen per group in the analysis, and within-group comparisons against baseline rather than between-group differences for the interferon findings — that is a weaker inferential structure than the p values suggest. It cannot establish that azithromycin prevents exacerbations, and it does not need to: the clinical effect is already established from larger trials.
What it offers is a plausible mechanism for that established effect, and one that is not antibacterial. Impaired epithelial interferon responses are a long-standing candidate explanation for why viral infections trigger asthma exacerbations, and a drug that restores them while lowering an alarmin is doing something more interesting than killing bacteria.
- Mechanistic study of 40 patients, 16 per group analysed
- Interferon findings are within-group against baseline, not between-group
- Clinical outcomes improved numerically but not significantly
- Suggests a non-antibacterial mechanism for an established clinical effect
- Does not address the antimicrobial resistance cost of long-term macrolides
The statistics, in plain English
The key limitation is in how the comparison was framed. Reporting that a marker rose significantly within the treatment group and did not within placebo is not the same as showing the two groups differ — that requires a direct between-group test, which is not reported here. With sixteen per group, the study is powered for large mechanistic signals and nothing else.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for pulmonology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free